You are here
AdvaMed/AdvaMedDx Statement on Cancer Moonshot Blue Ribbon Panel Report
WASHINGTON, DC – Scott Whitaker, president and CEO of the Advanced Medical Technology Association (AdvaMed), and Andy Fish, executive director of AdvaMedDx, today jointly issued the following statement on the Cancer Moonshot Blue Ribbon Panel Report:
“The report issued yesterday by Vice President Biden’s Cancer Moonshot Initiative is an encouraging step forward in achieving the important goal of eliminating cancer as we know it. We commend the Blue Ribbon panel and their working groups on this crucial effort.
“In particular, we applaud the panel for including recommendations on supporting the development of new cancer technologies that will accelerate testing of therapies and characterization of tumors,” said Whitaker. “The medical technology industry contributes roughly $2 billion annually to the R&D that is producing products and technologies that support the diagnosis and treatment of people living with cancer. AdvaMed and AdvaMedDx member companies stand ready to support the recommendations by continuing to develop the much-needed technologies necessary to improve cancer treatment and care,” Whitaker said.
Fish added, “The Blue Ribbon panel’s recommendations underscore the critical role of diagnostic testing as a cornerstone of cancer care and the enabler of precision medicine. Many of the panel’s recommended activities will be driven by the use of diagnostics and contribute to the continued development of advanced diagnostic technologies and tests, including retrospective biospecimen analysis, networked data sharing, therapeutic target identification, and screening and early detection. We note that appropriate public policies – especially with regard to regulation and reimbursement, as well as access to biospecimens – are essential to ensuring robust progress in the research, development, commercialization and utilization of advanced diagnostic technologies.
“We hope that as the panel moves forward in implementing their recommendations that the remarkable developments and technological advances already available to diagnose and treat cancer are not forgotten as critical pieces of the cancer management puzzle. These include the diagnostic tests and imaging technologies that provide vital information that guide cancer diagnosis and treatment, as well as the radiotherapy technologies that are safer and more targeted to a previously unimaginable precision, reducing the already minimal side effects and preserving the patient's healthy tissue.”
AdvaMed member companies produce the medical devices, diagnostic products and health information systems that are transforming health care through earlier disease detection, less invasive procedures and more effective treatments. AdvaMed members range from the largest to the smallest medical technology innovators and companies. For more information, visit www.advamed.org.
AdvaMedDx member companies produce innovative, safe and effective in vitro diagnostic tests that facilitate evidence-based medicine, improve quality of patient care, promote wellness, enable early detection of disease and reduce overall health care costs. Functioning as an association within AdvaMed, AdvaMedDx is dedicated to the issues facing in vitro diagnostic companies both in the United States and abroad.